American Cancer Society

Lack of clinical data overshadows opioid prescribing guidelines

Sunday, May 1, 2016

On March 18, 2016, the Centers for Disease Control (CDC) in Atlanta released its guidelines for prescribing opioids for chronic pain in outpatient settings outside of active cancer treatment, palliative care, and end-of-life care. The results were instantly controversial. While no one argues that opioid addiction has become a health crisis, critics claim that a scarcity of clinical trial data undermine the guidelines and could even lead to patients being harmed.

[Read More]

Three Questions: Wendy K.D. Selig, WSCollaborative

Monday, August 17, 2015

CWWeekly presents this feature as a way to put the spotlight on issues faced by executives in the clinical trials space. Wendy K.D. Selig is founder and CEO of WSCollaborative, a consulting firm that advises patient advocacy groups and other health-sector clients in defining and implementing strategies for collaborations with industry and government.

[Read More]

CRI and Cancer Immunology

Monday, April 27, 2015

The Pulse on Global Trials by Matthew Howes

Since being named “Breakthrough of the Year” by Science magazine less than two years ago, cancer immunology has been taken from the fringe to the forefront. 

[Read More]

Johnson & Johnson, Dana-Farber launch $10 million lung cancer collaboration

Thursday, June 26, 2014

Johnson & Johnson Innovation, Boston, and Janssen Biotech have announced a three-year immuno-oncology lung cancer collaboration with the Dana-Farber Cancer Institute. Janssen scientists will work with the research team at Dana-Farber’s Belfer Institute for Applied Cancer Science to determine the clinical setting for certain immuno-oncology agents in Janssen’s lung cancer discovery pipeline.

[Read More]